Restless Legs Syndrome (RLS)

Restless Legs Syndrome

References

1. Ekbom K. Restless legs syndrome. Acta Med Scand 1945;158:4-122.

2. McCrink L, Allen RP, Wolowacz S, Sherrill B, Connolly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: A multi-national study. Sleep Med 2006;6:73-83.

3. Garcia-Borreguero D. Time to REST: epidemiology and burden. Eur J Neurol 2006;13 Suppl 3:15-20.

4. Ulfberg J, Bjorvatn B, Leissner L, et al. Comorbidity in restless legs syndrome among a sample of Swedish adults. Sleep Med 2007;8:768-72.

5. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008;70:35-42.

6. Siddiqui F, Strus J, Ming X, Lee IA, Chokroverty S, Walters AS. Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol 2007;118:1923-30.

7. Pennestri MH, Montplaisir J, Colombo R, Lavigne G, Lanfranchi PA. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology 2007;68:1213-8.

8. Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep 2007;30:866-71.

9. Hanson M, Honour M, Singleton A, et al. Analysis of familial and sporadic restless legs syndrome in age of onset, gender, and severity features. J Neurol 2004;251:1398-401.

10. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 1996;46:92-5.

11. Winkelmann J, Wetter TC, Collado-Seidel V, et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000;23:597-602.

12. Bassetti CL, Mauerhofer D, Gugger M, Mathis J, Hess CW. Restless legs syndrome: a clinical study of 55 patients. European neurology 2001;45:67-74.

13. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000;1:11-9.

14. Botez MI, Lambert B. Folate deficiency and restless-legs syndrome in pregnancy. The New England journal of medicine 1977;297:670.

15. Goodman JD, Brodie C, Ayida GA. Restless leg syndrome in pregnancy. BMJ 1988;297:1101-2.

16. McParland P, Pearce JM. Restless leg syndrome in pregnancy. BMJ (Clinical research ed 1988;297:1543.

17. Suzuki K, Ohida T, Sone T, et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep 2003;26:673-7.

18. Manconi M, Ferini-Strambi L. Restless legs syndrome among pregnant women. Sleep 2004;27:350; author reply 1.

19. Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology 2004;63:1065-9.

20. Manconi M, Govoni V, De Vito A, et al. Pregnancy as a risk factor for restless legs syndrome. Sleep Med 2004;5:305-8.

21. Kirsch DB, Avidan AY. Pregnancy associated with daytime sleepiness and nighttime restlessness. Sleep Med 2005;6:473-4.

22. Bartell S, Zallek S. Intravenous magnesium sulfate may relieve restless legs syndrome in pregnancy. J Clin Sleep Med 2006;2:187-8.

23. Tunc T, Karadag YS, Dogulu F, Inan LE. Predisposing factors of restless legs syndrome in pregnancy. Mov Disord 2007;22:627-31.

24. Telarovic S, Relja M, Trkulja V. Restless legs syndrome in hemodialysis patients: association with calcium antagonists. A preliminary report. European neurology 2007;58:166-9.

25. Murtagh FE, Addington-Hall JM, Edmonds PM, et al. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J Palliat Med 2007;10:1266-76.

26. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Advances in chronic kidney disease 2007;14:82-99.

27. Gusbeth-Tatomir P, Boisteanu D, Seica A, Buga C, Covic A. Sleep disorders: a systematic review of an emerging major clinical issue in renal patients. International urology and nephrology 2007;39:1217-26.

28. Perl J, Unruh ML, Chan CT. Sleep disorders in end-stage renal disease: 'Markers of inadequate dialysis'? Kidney Int 2006;70:1687-93.

29. Novak M, Mendelssohn D, Shapiro CM, Mucsi I. Diagnosis and management of sleep apnea syndrome and restless legs syndrome in dialysis patients. Sem Dialysis 2006;19:210-6.

30. Noda A, Nakai S, Soga T, et al. Factors contributing to sleep disturbance and hypnotic drug use in hemodialysis patients. Intern Med 2006;45:1273-8.

31. Molnar MZ, Novak M, Mucsi I. Management of restless legs syndrome in patients on dialysis. Drugs 2006;66:607-24.

32. Lee JH, Parker KP, Ansari FP, Bliwise DL. A secondary analysis of racial differences in periodic leg movements in sleep and ferritin in hemodialysis patients. Sleep Med 2006;7:646-8.

33. Kawauchi A, Inoue Y, Hashimoto T, et al. Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. Clin Nephrol 2006;66:440-6.

34. Siddiqui S, Kavanagh D, Traynor J, Mak M, Deighan C, Geddes C. Risk factors for restless legs syndrome in dialysis patients. Nephron 2005;101:c155-60.

35. Mucsi I, Molnar MZ, Ambrus C, et al. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant 2005;20:571-7.

36. Unruh ML, Levey AS, D'Ambrosio C, Fink NE, Powe NR, Meyer KB. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis 2004;43:900-9.

37. Rijsman RM, de Weerd AW, Stam CJ, Kerkhof GA, Rosman JB. Periodic limb movement disorder and restless legs syndrome in dialysis patients. Nephrology (Carlton, Vic 2004;9:353-61.

38. Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004;43:763-71.

39. Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004;5:309-15.

40. Cirignotta F, Mondini S, Santoro A, Ferrari G, Gerardi R, Buzzi G. Reliability of a questionnaire screening restless legs syndrome in patients on chronic dialysis. Am J Kidney Dis 2002;40:302-6.

41. Winkelman JW. Restless legs syndrome in ESRD. Nephrol News Issues 1999;13:27, 31-2.

42. Collado-Seidel V, Kohnen R, Samtleben W, Hillebrand GF, Oertel WH, Trenkwalder C. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998;31:324-8.

43. Matthews WB. Iron deficiency and restless legs. BMJ 1976;1:898.

44. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age and ageing 1994;23:200-3.

45. Krieger J, Schroeder C. Iron, brain and restless legs syndrome. Sleep Med Rev 2001;5:277-86.

46. Akyol A, Kiylioglu N, Kadikoylu G, Bolaman AZ, Ozgel N. Iron deficiency anemia and restless legs syndrome: is there an electrophysiological abnormality? Clin Neurol Neurosurg 2003;106:23-7.

47. Silber MH, Richardson JW. Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clin Proc 2003;78:52-4.

48. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004;5:385-91.

49. O'Keeffe ST. Iron deficiency with normal ferritin levels in restless legs syndrome. Sleep Med 2005;6:281-2.

50. Picchietti D. Is iron deficiency an underlying cause of pediatric restless legs syndrome and of attention-deficit/hyperactivity disorder? Sleep Med 2007;8:693-4.

51. Blom S, Ekbom KA. Comparison between akathisia developing on treatment with phenothiazine derivatives and the restless legs syndrome. Acta Med Scand 1961;170:689-94.

52. Ward NG. Akathisia associated with droperidol during epidural anesthesia. Anesthesiology 1989;71:786-7.

53. Nishimatsu O, Horiguchi J, Inami Y, Sukegawa T, Sasaki A. Periodic limb movement disorder in neuroleptic-induced akathisia. The Kobe J Med Sci1997;43:169-77.

54. Banno K, Delaive K, Walld R, Kryger MH. Restless legs syndrome in 218 patients: associated disorders. Sleep Med 2000;1:221-9.

55. Winkelmann J, Schadrack J, Wetter TC, Zieglgansberger W, Trenkwalder C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med 2001;2:57-61.

56. Ehrenberg BL. Acute migraine treatment with droperidol. Neurology 2003;61:1826.

57. Young WB, Piovesan EJ, Biglan KM. Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spect 2003;8:450-6.

58. Elzinga-Huttenga J, Hekster Y, Bijl A, Rotteveel J. Movement disorders induced by gastrointestinal drugs: two paediatric cases. Neuropediatrics 2006;37:102-6.

59. O'Sullivan RL, Greenberg DB. H2 antagonists, restless leg syndrome, and movement disorders. Psychosomatics 1993;34:530-2.

60. Lipinski JF, Jr., Mallya G, Zimmerman P, Pope HG, Jr. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989;50:339-42.

61. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997;58:348-50.

62. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005;65:927-47.

63. Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005;58:510-4.

64. Lecendreux M, Cortese S. Sleep problems associated with ADHD: a review of current therapeutic options and recommendations for the future. Exp Rev Neurotherap 2007;7:1799-806.

65. Cortese S, Lecendreux M, Bernardina BD, Mouren MC, Sbarbati A, Konofal E. Attention-deficit/hyperactivity disorder, Tourette's syndrome, and restless legs syndrome: the iron hypothesis. Med Hypotheses 2007.

66. Schredl M, Alm B, Sobanski E. Sleep quality in adult patients with attention deficit hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2007;257:164-8.

67. Philipsen A, Hornyak M, Riemann D. Sleep and sleep disorders in adults with attention deficit/hyperactivity disorder. Sleep Med Rev 2006;10:399-405.

68. Cortese S, Konofal E, Lecendreux M, et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep 2005;28:1007-13.

69. Oner P, Dirik EB, Taner Y, Caykoylu A, Anlar O. Association between low serum ferritin and restless legs syndrome in patients with attention deficit hyperactivity disorder. The Tohoku J Exper Med 2007;213:269-76.

70. Konofal E, Cortese S, Marchand M, Mouren MC, Arnulf I, Lecendreux M. Impact of restless legs syndrome and iron deficiency on attention-deficit/hyperactivity disorder in children. Sleep Med 2007;8:711-5.

71. Ekbom KA. Growing pains and restless legs. Acta Paediatri Scand 1975;64:264-6.

72. Walters AS. Is there a subpopulation of children with growing pains who really have restless legs syndrome? A review of the literature. Sleep Med 2002;3:93-8.

73. Rajaram SS, Walters AS, England SJ, Mehta D, Nizam F. Some children with growing pains may actually have restless legs syndrome. Sleep 2004;27:767-73.

74. Gamaldo CE, Benbrook AR, Allen RP, Scott JA, Henning WA, Earley CJ. Childhood and adult factors associated with restless legs syndrome (RLS) diagnosis. Sleep Med 2007;8:716-22.

75. Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A, Ferini-Strambi L. Restless legs syndrome: prevalence and impact in children and adolescents—the Peds REST study. Pediatrics 2007;120:253-66.

76. Picchietti DL, Stevens HE. Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med 2007.

77. Pichler I, Hicks AA, Pramstaller PP. Restless legs syndrome: an update on genetics and future perspectives. Clin Genet 2007.

78. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007;357:639-47.

79. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39:1000-6.

80. Unrath A, Juengling FD, Schork M, Kassubek J. Cortical grey matter alterations in idiopathic restless legs syndrome: an optimized voxel-based morphometry study. Mov Disord 2007;22:1751-6.

81. Spiegelhalder K, Feige B, Paul D, et al. Cerebral correlates of muscle tone fluctuations in restless legs syndrome: a pilot study with combined functional magnetic resonance imaging and anterior tibial muscle electromyography. Sleep Med 2008;24:167-80.

82. Hilker R, Burghaus L, Razai N, Jacobs AH, Szelies B, Heiss WD. Functional brain imaging in combined motor and sleep disorders. J Neurol Sci 2006;248:223-6.

83. Earley CJ, P BB, Horska A, Allen RP. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Med 2006;7:458-61.

84. Cervenka S, Palhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006;129:2017-28.

85. von Spiczak S, Whone AL, Hammers A, et al. The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain 2005;128:906-17.

86. Mrowka M, Jobges M, Berding G, Schimke N, Shing M, Odin P. Computerized movement analysis and beta-CIT-SPECT in patients with restless legs syndrome. J Neural Transm 2005;112:693-701.

87. Etgen T, Draganski B, Ilg C, et al. Bilateral thalamic gray matter changes in patients with restless legs syndrome. NeuroImage 2005;24:1242-7.

88. Wetter TC, Eisensehr I, Trenkwalder C. Functional neuroimaging studies in restless legs syndrome. Sleep Med 2004;5:401-6.

89. Tribl GG, Asenbaum S, Happe S, Bonelli RM, Zeitlhofer J, Auff E. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep. Nucl Med Communicat 2004;25:55-60.

90. Schmidauer C, Sojer M, Seppi K, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 2005;58:630-4.

91. Winkelmann J, Polo O, Provini F, et al. Genetics of restless legs syndrome (RLS): state-of-the-art and future directions. Mov Disord 2007:S449-S58.

92. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007;22:S440-8.

93. Allen RP. Race, iron status and restless legs syndrome. Sleep Med 2002;3:467-8.

94. Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004;43:663-70.

95. Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004;5:231-5.

96. Kemlink D, Sonka K, Pretl M, Benakova H. Suggestive evidence of erythropoietin level abnormality in patients with sporadic and familial cases of the restless legs syndrome. Neuro endocrinology letters 2007;28:643-6.

97. Harris DC, Chapman JR, Stewart JH, Lawrence S, Roger SD. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Austral NZ J Med 1991;21:693-700.

98. Kryger MH, Otake K, Foerster J. Low body stores of iron and restless legs syndrome: a correctable cause of insomnia in adolescents and teenagers. Sleep Med 2002;3:127-32.

99. Stiasny-Kolster K, Magerl W, Oertel WH, Moller JC, Treede RD. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 2004;127:773-82.

100. Bara-Jimenez W, Aksu M, Graham B, Sato S, Hallett M. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 2000;54:1609-16.

101. Schattschneider J, Bode A, Wasner G, Binder A, Deuschl G, Baron R. Idiopathic restless legs syndrome: abnormalities in central somatosensory processing. J Neurol 2004;251:977-82.

102. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994;17:739-43.

103. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 2000;54:1064-8.

104. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547-54.

105. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5:237-46.

106. Rijsman R, Neven AK, Graffelman W, Kemp B, de Weerd A. Epidemiology of restless legs in The Netherlands. Eur J Neurol 2004;11:607-11.

107. Van De Vijver DA, Walley T, Petri H. Epidemiology of restless legs syndrome as diagnosed in UK primary care. Sleep Med 2004;5:435-40.

108. Bjorvatn B, Leissner L, Ulfberg J, et al. Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med 2005;6:307-12.

109. Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Hasnaoui A. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005;65:239-46.

110. Phillips B, Hening W, Britz P, Mannino D. Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll. Chest 2006;129:76-80.

111. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006;7:545-52.

112. O'Keeffe ST, Egan D, Myers A, Redmond S. The frequency and impact of restless legs syndrome in primary care. Ir Med J 2007;100:539-42.

113. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000;160:2137-41.

114. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001;16:1159-63.

115. Ulfberg J, Nystrom B, Carter N, Edling C. Restless Legs Syndrome among working-aged women. Eur Neurol 2001;46:17-9.

116. Kageyama T, Kabuto M, Nitta H, et al. Prevalences of periodic limb movement-like and restless legs-like symptoms among Japanese adults. Psychiatry Clin Neurosci 2000;54:296-8.

117. Garcia-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006;10:153-67.

118. Tan EK, Seah A, See SJ, Lim E, Wong MC, Koh KK. Restless legs syndrome in an Asian population: A study in Singapore. Mov Disord 2001;16:577-9.

119. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.

120. Chabli A, Michaud M, Montplaisir J. Periodic arm movements in patients with the restless legs syndrome. Eur Neurol 2000;44:133-8.

121. Freedom T, Merchut MP. Arm restlessness as the initial symptom in restless legs syndrome. Arch Neurol 2003;60:1013-5.

122. Michaud M, Chabli A, Lavigne G, Montplaisir J. Arm restlessness in patients with restless legs syndrome. Mov Disord 2000;15:289-93.

123. Buchfuhrer MJ. Restless legs syndrome (RLS) with expansion of symptoms to the face. Sleep Med 2007.

124. Allen RP. Improving RLS diagnosis and severity assessment: polysomnography, actigraphy and RLS-sleep log. Sleep Med 2007;8 Suppl 2:S13-8.

125. Aksu M, Demirci S, Bara-Jimenez W. Correlation between putative indicators of primary restless legs syndrome severity. Sleep Med 2007;8:84-9.

126. Michaud M. Is the suggested immobilization test the "gold standard" to assess restless legs syndrome? Sleep Med 2006;7:541-3.

127. Haba-Rubio J, Sforza E. Test-to-test variability in motor activity during the suggested immobilization test in restless legs patients. Sleep Med 2006;7:561-6.

128. Aksu M, Demirci S, Bara-Jimenez W. Correlation between putative indicators of primary restless legs syndrome severity. Sleep Med 2007;8:84-9.

129. Birinyi PV, Allen RP, Lesage S, Dean T, Earley CJ. Investigation into the correlation between sensation and leg movement in restless legs syndrome. Mov Disord 2005;20:1097-103.

130. Allen RP, Dean T, Earley CJ. Effects of rest-duration, time-of-day and their interaction on periodic leg movements while awake in restless legs syndrome. Sleep Med 2005;6:429-34.

131. Baier PC, Trenkwalder C. Circadian variation in restless legs syndrome. Sleep Med 2007;8:645-50.

132. Hogl B. Circadian rhythms in RLS. Sleep Med 2006;7:209-10.

133. Earley CJ, Hyland K, Allen RP. Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med 2006;7:263-8.

134. Michaud M, Dumont M, Paquet J, Desautels A, Fantini ML, Montplaisir J. Circadian variation of the effects of immobility on symptoms of restless legs syndrome. Sleep 2005;28:843-6.

135. Michaud M, Dumont M, Selmaoui B, Paquet J, Fantini ML, Montplaisir J. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol 2004;55:372-80.

136. Allen RP, La Buda MC, Becker P, Earley CJ. Family history study of the restless legs syndrome. Sleep Med 2002;3 Suppl:S3-7.

137. von Scheele C. Levodopa in restless legs. Lancet 1986;2:426-7.

138. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-8.

139. Kaplan B, Mason NA. Levodopa in restless legs syndrome. Ann Pharmacotherapy 1992;26:214-6.

140. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717-23.

141. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999;52:285-90.

142. Trenkwalder C, Collado Seidel V, Kazenwadel J, et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov Disord 2003;18:1184-9.

143. Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004;251:579-83.

144. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916-22.

145. Partinen M. Challenging issues: sleep-wake, augmentation and quality of life. Sleep Med 2007;8 Suppl 2:S19-24.

146. McCrink L, Allen RP, Wolowacz S, Sherrill B, Connolly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med 2007;8:73-83.

147. Littner MR. Predictors of health-related quality of life in restless legs syndrome: which trees are in the forest? Sleep Med 2007;8:8-9.

148. Kushida CA. Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome. The Am J Med 2007;120:S4-S12.

149. Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007;16:617-24.

150. Schillevoort I, van Puijenbroek EP, de Boer A, Roos RA, Jansen PA, Leufkens HG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002;17:75-9.

151. Kim SW, Shin IS, Kim JM, Yang SJ, Shin HY, Yoon JS. Bupropion may improve restless legs syndrome: a report of three cases. Clinical Neuropharmacol 2005;28:298-301.

152. Lutz EG. Restless legs, anxiety and caffeinism. The J Clin Psychiatry 1978;39:693-8.

153. Merlino G, Valente M, Serafini A, Gigli GL. Restless legs syndrome: diagnosis, epidemiology, classification and consequences. Neurol Sci 2007;28 Suppl 1:S37-46.

154. Hornyak M, Feige B, Voderholzer U, Philipsen A, Riemann D. Polysomnography findings in patients with restless legs syndrome and in healthy controls: a comparative observational study. Sleep 2007;30:861-5.

155. Abetz L, Arbuckle R, Allen RP, et al. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Med 2006;7:340-9.

156. Wunderlich GR, Evans KR, Sills T, et al. An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med 2005;6:131-9.

157. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-32.

158. Garcia-Borreguero D, Larrosa O, de la Llave Y, Granizo JJ, Allen R. Correlation between rating scales and sleep laboratory measurements in restless legs syndrome. Sleep Med 2004;5:561-5.

159. Allen RP, Earley CJ. Validation of the Johns Hopkins restless legs severity scale. Sleep Med 2001;2:239-42.

160. Kohnen R, Allen RP, Benes H, et al. Assessment of restless legs syndrome--methodological approaches for use in practice and clinical trials. Mov Disord 2007;22:S485-S94.

161. Hogl B, Gschliesser V. RLS assessment and sleep questionnaires in practice--lessons learned from Parkinson's disease. Sleep Med 2007;8 Suppl 2:S7-12.

162. Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Val Health 2005;8:157-67.

163. Abetz L, Arbuckle R, Allen RP, Mavraki E, Kirsch J. The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. Health Qual Life Outcomes 2005;3:79.

164. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Therapeut 2004;26:925-35.

165. Barton JC, Wooten VD, Acton RT. Hemochromatosis and iron therapy of Restless Legs Syndrome. Sleep Med 2001;2:249-51.

166. Agarwal R. Nonhematological benefits of iron. American J Nephrol 2007;27:565-71.

167. Earley CJ, Heckler D, Allen RP. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med 2005;6:301-5.

168. Rangarajan S, D'Souza GA. Restless legs syndrome in Indian patients having iron deficiency anemia in a tertiary care hospital. Sleep Med 2007;8:247-51.

169. Allen RP. Iron, RLS and blood donations. Sleep Med 2004;5:113-4.

170. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007;8:742-52.

171. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-9.

172. Trenkwalder C. The weight of evidence for ropinirole in restless legs syndrome. Eur J Neurol 2006;13 Suppl 3:21-30.

173. Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006;67:1040-6.

174. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21:1627-35.

175. Kushida CA. Pramipexole for the treatment of restless legs syndrome. Exp Opin Pharmacotherapy 2006;7:441-51.

176. Giorgi L, Ritchie SY, Kirsch JM. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme. Curr Med Res Opin 2006;22:1867-77.

177. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:17-27.

178. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-23.

179. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-7.

180. Garcia-Borreguero D. Augmentation: understanding a key feature of RLS. Sleep Med 2004;5:5-6.

181. Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006;5:878-86.

182. Vetrugno R, La Morgia C, D'Angelo R, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord 2007;22:424-7.

183. Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2007.

184. Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-30.

185. Kurlan R, Richard IH, Deeley C. Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation. J Gen Intern Med 2006;21:1338.

186. Janzen L, Rich JA, Vercaigne LM. An overview of levodopa in the management of restless legs syndrome in a dialysis population: pharmacokinetics, clinical trials, and complications of therapy. The Ann Pharmacotherapy 1999;33:86-92.

187. Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996;19:801-10.

188. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13.

189. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 2002;3 Suppl:S23-5.

190. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14.

191. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003;26:819-21.

192. Lin SC, Kaplan J, Burger CD, Fredrickson PA. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 1998;73:497-500.

193. Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 2006;21:1404-10.

194. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study—the PRELUDE study. Sleep Med 2006;7:407-17.

195. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2006.

196. Montplaisir J, Fantini ML, Desautels A, Michaud M, Petit D, Filipini D. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006;13:1306-11.

197. Merlino G, Dolso P, Canesin R, Cancelli I, Valente M, Gigli GL. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial. Neuropsychobiology 2006;54:195-200.

198. Stiasny-Kolster K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome. An open label trial. Neuropsychobiology 2004;50:65-70.

199. Miranda M, Kagi M, Fabres L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004;62:831-2.

200. Manconi M, Casetta I, Govoni V, Cesnik E, Ferini-Strambi L, Granieri E. Pramipexole in Restless Legs syndrome. Evaluation by suggested immobilization test. J Neurol 2003;250:1494-5.

201. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000;7 Suppl 1:27-31.

202. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938-43.

203. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:560-83.

204. Bliwise DL, Freeman A, Ingram CD, Rye DB, Chakravorty S, Watts RL. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005;6:141-7.

205. Pellecchia MT, Vitale C, Sabatini M, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol 2004;27:178-81.

206. Adler CH, Hauser RA, Sethi K, et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 2004;62:1405-7.

207. Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2007.

208. Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-8.

209. Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007;30:249-55.

210. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007;68:301-3.

211. von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990;47:1223-4.

212. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982;39:739.

213. Mitler MM, Browman CP, Menn SJ, Gujavarty K, Timms RM. Nocturnal myoclonus: treatment efficacy of clonazepam and temazepam. Sleep 1986;9:385-92.

214. Chesson AL, Jr., Wise M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999;22:961-8.

215. Matthews WB. Treatment of the restless legs syndrome with clonazepam. BMJ 1979;1:751.

216. Montagna P, Sassoli de Bianchi L, Zucconi M, Cirignotta F, Lugaresi E. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984;69:428-30.

217. Sandyk R, Gillman MA. The opioid system in the restless legs and nocturnal myoclonus syndromes. Sleep 1986;9:370-1.

218. Kavey N, Walters AS, Hening W, Gidro-Frank S. Opioid treatment of periodic movements in sleep in patients without restless legs. Neuropeptides 1988;11:181-4.

219. Montplaisir J, Lapierre O, Warnes H, Pelletier G. The treatment of the restless leg syndrome with or without periodic leg movements in sleep. Sleep 1992;15:391-5.

220. Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. The J Clin Psychiatry 1999;60:241-4.

221. Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001;16:1105-9.

222. Hening WA. Current guidelines and standards of practice for restless legs syndrome. The Am J Med 2007;120:S22-7.

223. Zucconi M, Coccagna G, Petronelli R, Gerardi R, Mondini S, Cirignotta F. Nocturnal myoclonus in restless legs syndrome effect of carbamazepine treatment. Func Neurol 1989;4:263-71.

224. Larsen S, Telstad W, Sorensen O, Thom E, Stensrud P, Nyberg-Hansen R. Carbamazepine therapy in restless legs. Discrimination between responders and non-responders. Acta Med Scand 1985;218:223-7.

225. Telstad W, Sorensen O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R. Treatment of the restless legs syndrome with carbamazepine: a double blind study. BMJ 1984;288:444-6.

226. Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs. A controlled pilot study. Eur J Clin Pharmacol 1983;25:323-4.

227. Micozkadioglu H, Ozdemir FN, Kut A, Sezer S, Saatci U, Haberal M. Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Renal Failure 2004;26:393-7.

228. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol 1997;20:148-51.

229. Mellick GA, Mellick LB. Management of restless legs syndrome with gabapentin (Neurontin). Sleep 1996;19:224-6.

230. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001;38:104-8.

231. Youssef EA, Wagner ML, Martinez JO, Hening W. Pilot trial of lamotrigine in the restless legs syndrome. Sleep Med 2005;6:89.

232. Sommer M, Bachmann CG, Liebetanz KM, Schindehutte J, Tings T, Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007;115:347-50.

233. Zoe A, Wagner ML, Walters AS. High-dose clonidine in a case of restless legs syndrome. The Ann Pharmacotherapy 1994;28:878-81.

234. Bastani B, Westervelt FB. Effectiveness of clonidine in alleviating the symptoms of "restless legs." Am J Kidney Dis 1987;10:326.

235. Handwerker JV, Jr., Palmer RF. Clonidine in the treatment of "restless leg" syndrome. N Engl J Med 1985;313:1228-9.

236. Sandyk R, Kwo-on-Yuen PF, Bamford CR. The effects of baclofen in the restless legs syndrome: evidence for endogenous opioid involvement. J Clin Psychopharmacol 1988;8:440-1.